Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odalasvir
- Development stage
- Phase 2
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Odalasvir is an investigational, orally administered, second-generation small molecule inhibitor of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A). NS5A is a multifunctional viral protein essential for HCV replication and plays a role in interferon resistance. By inhibiting NS5A, odalasvir disrupts viral replication and can help overcome treatment failure associated with interferon-based therapies. Odalasvir was developed by Achillion Pharmaceuticals and has been studied primarily for the treatment of chronic hepatitis C infection, including in combination regimens with other direct acting antivirals such as adafosbuvir (AL-335) and simeprevir. Clinical development reached phase II trials but was subsequently discontinued[1][3][7].
- Other names
- odalasvir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on odalasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odalasvir.